BR9502085A - Derivado de 11,21-bis-fenil-19-norpregnano,processo de preparação do mesmo e composição farmaceutica - Google Patents
Derivado de 11,21-bis-fenil-19-norpregnano,processo de preparação do mesmo e composição farmaceuticaInfo
- Publication number
- BR9502085A BR9502085A BR9502085A BR9502085A BR9502085A BR 9502085 A BR9502085 A BR 9502085A BR 9502085 A BR9502085 A BR 9502085A BR 9502085 A BR9502085 A BR 9502085A BR 9502085 A BR9502085 A BR 9502085A
- Authority
- BR
- Brazil
- Prior art keywords
- nr5r6
- alkyl
- norpregnane
- bis
- phenyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 239000003862 glucocorticoid Substances 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0005—Oxygen-containing hetero ring
- C07J71/001—Oxiranes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
- C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Seasonings (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94201431 | 1994-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9502085A true BR9502085A (pt) | 1996-03-05 |
Family
ID=8216894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9502085A BR9502085A (pt) | 1994-05-19 | 1995-05-18 | Derivado de 11,21-bis-fenil-19-norpregnano,processo de preparação do mesmo e composição farmaceutica |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5620966A (pt) |
| EP (1) | EP0683172B1 (pt) |
| JP (1) | JP3814312B2 (pt) |
| KR (1) | KR100359474B1 (pt) |
| CN (1) | CN1042539C (pt) |
| AT (1) | ATE156836T1 (pt) |
| AU (1) | AU701616B2 (pt) |
| BR (1) | BR9502085A (pt) |
| CA (1) | CA2149496C (pt) |
| DE (1) | DE69500542T2 (pt) |
| DK (1) | DK0683172T3 (pt) |
| ES (1) | ES2106616T3 (pt) |
| FI (1) | FI112491B (pt) |
| GR (1) | GR3025225T3 (pt) |
| HU (1) | HU217429B (pt) |
| NO (1) | NO304379B1 (pt) |
| NZ (1) | NZ272143A (pt) |
| PL (1) | PL180481B1 (pt) |
| RU (1) | RU2152952C2 (pt) |
| ZA (1) | ZA953976B (pt) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL118974A (en) * | 1995-08-17 | 2001-09-13 | Akzo Nobel Nv | History 11 - (Transformed Phenyl) - Astra - 4, 9 - Diane, their preparation and pharmaceutical preparations containing them |
| TR200103104T2 (tr) | 1999-04-30 | 2002-05-21 | Pfizer Products Inc. | Glukortikoid alıcı modülatörleri |
| US7713989B2 (en) | 2000-04-27 | 2010-05-11 | Dow Robert L | Glucocorticoid receptor modulators |
| EP1201660B1 (en) | 2000-10-30 | 2005-08-31 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
| EP1285927A3 (de) | 2001-08-16 | 2005-06-29 | Schering Aktiengesellschaft | Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems |
| AU2002366217A1 (en) | 2001-11-23 | 2003-06-10 | Akzo Nobel N.V. | Treatment of major depressive disorder using glucocorticoid receptor antagonists |
| US7250408B2 (en) | 2002-12-16 | 2007-07-31 | Bayer Schering Pharma Ag | Glucocorticoid receptor antagonists for prophylaxis and therapy of glucocorticoid-mediated hypogonadism, of sexual dysfunction and/or infertility |
| JP4970932B2 (ja) * | 2003-03-11 | 2012-07-11 | トロフォ | コレスト−４−エン−３−オンの誘導体の医薬としての使用、これらを含む医薬組成物、新規誘導体及びそれらの製造方法 |
| CN107007581A (zh) | 2006-08-24 | 2017-08-04 | 田纳西大学研究基金会 | 取代的n‑酰基苯胺及其使用方法 |
| US10987334B2 (en) | 2012-07-13 | 2021-04-27 | University Of Tennessee Research Foundation | Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs) |
| US10314807B2 (en) | 2012-07-13 | 2019-06-11 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| US9969683B2 (en) | 2012-07-13 | 2018-05-15 | Gtx, Inc. | Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS) |
| US10258596B2 (en) | 2012-07-13 | 2019-04-16 | Gtx, Inc. | Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS) |
| CN108143728A (zh) | 2012-07-13 | 2018-06-12 | Gtx公司 | 选择性雄激素受体调节剂在治疗乳癌中的用途 |
| US9622992B2 (en) | 2012-07-13 | 2017-04-18 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| US9744149B2 (en) | 2012-07-13 | 2017-08-29 | Gtx, Inc. | Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs) |
| EP3265127B1 (en) | 2015-03-02 | 2024-02-21 | Corcept Therapeutics, Inc. | Mifepristone and octreotide for use in the treatment of cushing's syndrome in a patient having an adrenocorticotropic hormone (acth)-secreting pancreatic neuroendocrine tumor |
| CN107530339B (zh) | 2015-03-30 | 2021-03-16 | 科赛普特治疗学股份有限公司 | 糖皮质激素受体拮抗剂联合糖皮质激素用于治疗肾上腺功能不全 |
| EP3335043B1 (en) | 2015-08-13 | 2021-03-31 | Corcept Therapeutics, Inc. | Method for differentially diagnosing acth-dependent cushing's syndrome |
| CN105254697A (zh) * | 2015-11-17 | 2016-01-20 | 湖南成大生物科技有限公司 | △16甾体类化合物的制备方法 |
| SG11201806101SA (en) | 2016-01-19 | 2018-08-30 | Corcept Therapeutics Inc | Differential diagnosis of ectopic cushing's syndrome |
| EP3214092A1 (en) * | 2016-03-04 | 2017-09-06 | Bayer Pharma Aktiengesellschaft | Prodrugs of the selective progesterone receptor modulator (sprm) (11.beta.,17.beta.)-17-hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one |
| MX393313B (es) | 2017-06-20 | 2025-03-24 | Corcept Therapeutics Inc | Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide. |
| CN114456223B (zh) * | 2022-01-24 | 2023-07-21 | 湖南科益新生物医药有限公司 | 3-缩酮的合成方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1515284A (en) * | 1974-05-21 | 1978-06-21 | Gastaud J | Pharmaceutical compositions containing progestogens derived from the 17-alpha-hydroxy-19-nor-progesterone series |
| FR2528434B1 (fr) * | 1982-06-11 | 1985-07-19 | Roussel Uclaf | Nouveaux 19-nor steroides substitues en 11b et eventuellement en 2, leur procede de preparation et leur application comme medicament |
| ZA8231B (en) * | 1981-01-09 | 1982-11-24 | Roussel Uclaf | New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained |
| FR2522328B1 (fr) * | 1982-03-01 | 1986-02-14 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments |
| FR2639045B2 (fr) * | 1982-03-01 | 1994-07-29 | Roussel Uclaf | Nouveaux produits derives de la structure 3-ceto-delta-4,9-19-nor steroides et leur application comme medicaments |
| DE3461090D1 (en) * | 1983-02-18 | 1986-12-04 | Schering Ag | 11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them |
| FR2549067B1 (fr) * | 1983-06-14 | 1985-12-27 | Roussel Uclaf | Derives estradieniques radioactifs marques au tritium, leur procede de preparation et leur application pour l'etude et le dosage radio-immunologique de steroides dans les fluides biologiques |
| US4780461A (en) * | 1983-06-15 | 1988-10-25 | Schering Aktiengesellschaft | 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same |
| DE3347126A1 (de) * | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| DE3410880A1 (de) * | 1984-03-21 | 1985-10-03 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 17-substituierte estradiene und estratriene |
| DE3506785A1 (de) * | 1985-02-22 | 1986-08-28 | Schering AG, Berlin und Bergkamen, 1000 Berlin | 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| US4771042A (en) * | 1985-11-25 | 1988-09-13 | The Upjohn Company | Inhibition of angiogenesis involving the coadministration of steroids with heparin or heparin fragments |
| FR2598421B1 (fr) | 1986-05-06 | 1988-08-19 | Roussel Uclaf | Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| DE3625315A1 (de) * | 1986-07-25 | 1988-01-28 | Schering Ag | 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate |
| US4774236A (en) * | 1986-09-17 | 1988-09-27 | Research Triangle Institute | 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them |
| ES2053714T3 (es) * | 1987-12-12 | 1994-08-01 | Akzo Nv | Proceso para la preparacion de 11-arilesteroides. |
| BE1004905A4 (fr) * | 1987-12-30 | 1993-02-23 | Roussel Uclaf | Nouveaux derives 17beta-oh 19-nor steroides substitues en 17alpha, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant. |
| US4954490A (en) * | 1988-06-23 | 1990-09-04 | Research Triangle Institute | 11 β-substituted progesterone analogs |
| DE3822770A1 (de) * | 1988-07-01 | 1990-01-04 | Schering Ag | 13-alkyl-11ss-phenylgonane |
| DE3832303A1 (de) * | 1988-09-20 | 1990-04-12 | Schering Ag | 11ss-phenyl-14ssh-steroide |
| FR2643638B1 (fr) * | 1989-02-24 | 1991-06-14 | Roussel Uclaf | Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
| FR2644789B1 (fr) * | 1989-03-22 | 1995-02-03 | Roussel Uclaf | Nouveaux steroides 19-nor, 3-ceto comportant une chaine en 17 aminosubstituee, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant |
| EP0411736B1 (de) * | 1989-08-04 | 1994-05-04 | Schering Aktiengesellschaft | 11 Beta-substituierte 16 alpha, 17alpha-Methylen-estra-4,9-dien-3-one |
| US5276023A (en) * | 1989-08-08 | 1994-01-04 | Roussel Uclaf | 19-nor-steroid esters |
| FR2651435A1 (fr) * | 1989-09-07 | 1991-03-08 | Roussel Uclaf | Nouvelle utilisation de composes anti-progestomimetiques. |
| US5407928A (en) * | 1990-08-15 | 1995-04-18 | Schering Aktiengesellschaft | 11β-aryl-gona-4,9-dien-3-ones |
| DK0712311T3 (da) * | 1993-08-04 | 1999-06-21 | Akzo Nobel Nv | Antiglucocorticoidsteroider til behandling af angstlidelser |
-
1995
- 1995-05-16 CA CA002149496A patent/CA2149496C/en not_active Expired - Fee Related
- 1995-05-16 ES ES95201268T patent/ES2106616T3/es not_active Expired - Lifetime
- 1995-05-16 EP EP95201268A patent/EP0683172B1/en not_active Expired - Lifetime
- 1995-05-16 DE DE69500542T patent/DE69500542T2/de not_active Expired - Fee Related
- 1995-05-16 DK DK95201268.0T patent/DK0683172T3/da active
- 1995-05-16 AT AT95201268T patent/ATE156836T1/de not_active IP Right Cessation
- 1995-05-16 ZA ZA953976A patent/ZA953976B/xx unknown
- 1995-05-17 NZ NZ272143A patent/NZ272143A/en unknown
- 1995-05-18 JP JP12005195A patent/JP3814312B2/ja not_active Expired - Fee Related
- 1995-05-18 HU HU9501461A patent/HU217429B/hu not_active IP Right Cessation
- 1995-05-18 AU AU20133/95A patent/AU701616B2/en not_active Ceased
- 1995-05-18 PL PL95308666A patent/PL180481B1/pl not_active IP Right Cessation
- 1995-05-18 KR KR1019950012374A patent/KR100359474B1/ko not_active Expired - Fee Related
- 1995-05-18 FI FI952424A patent/FI112491B/fi active
- 1995-05-18 NO NO951968A patent/NO304379B1/no unknown
- 1995-05-18 BR BR9502085A patent/BR9502085A/pt not_active IP Right Cessation
- 1995-05-18 RU RU95107892/04A patent/RU2152952C2/ru not_active IP Right Cessation
- 1995-05-18 CN CN95105395A patent/CN1042539C/zh not_active Expired - Fee Related
- 1995-05-19 US US08/445,119 patent/US5620966A/en not_active Expired - Fee Related
-
1997
- 1997-10-30 GR GR970402861T patent/GR3025225T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL180481B1 (pl) | 2001-02-28 |
| AU701616B2 (en) | 1999-02-04 |
| HUT71804A (en) | 1996-02-28 |
| KR100359474B1 (ko) | 2003-03-12 |
| EP0683172A1 (en) | 1995-11-22 |
| FI952424L (fi) | 1995-11-20 |
| DE69500542D1 (de) | 1997-09-18 |
| NO951968L (no) | 1995-11-20 |
| ZA953976B (en) | 1996-01-19 |
| DK0683172T3 (da) | 1998-03-30 |
| CA2149496C (en) | 2006-12-19 |
| HU217429B (hu) | 2000-01-28 |
| FI112491B (fi) | 2003-12-15 |
| PL308666A1 (en) | 1995-11-27 |
| NO304379B1 (no) | 1998-12-07 |
| DE69500542T2 (de) | 1998-01-02 |
| CA2149496A1 (en) | 1995-11-20 |
| ATE156836T1 (de) | 1997-08-15 |
| JPH07316187A (ja) | 1995-12-05 |
| FI952424A0 (fi) | 1995-05-18 |
| RU2152952C2 (ru) | 2000-07-20 |
| ES2106616T3 (es) | 1997-11-01 |
| NO951968D0 (no) | 1995-05-18 |
| NZ272143A (en) | 1995-11-27 |
| JP3814312B2 (ja) | 2006-08-30 |
| GR3025225T3 (en) | 1998-02-27 |
| KR950032267A (ko) | 1995-12-20 |
| CN1126727A (zh) | 1996-07-17 |
| CN1042539C (zh) | 1999-03-17 |
| RU95107892A (ru) | 1997-02-10 |
| AU2013395A (en) | 1995-11-30 |
| US5620966A (en) | 1997-04-15 |
| EP0683172B1 (en) | 1997-08-13 |
| HU9501461D0 (en) | 1995-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9502085A (pt) | Derivado de 11,21-bis-fenil-19-norpregnano,processo de preparação do mesmo e composição farmaceutica | |
| TW427887B (en) | Pharmaceutical composition comprising a benzimidazole derivative for treating viral infections | |
| GR3017996T3 (en) | 17-g(b)-SUBSTITUTED-4-AZA-5-g(a)-ANDROSTAN-3-ONE DERIVATIVES AND PROCESS FOR THEIR PREPARATION. | |
| GB9211172D0 (en) | Compounds | |
| PT849269E (pt) | Vinil-pirrolidina cefalosporinas com substituintes basicos | |
| DE69006452D1 (de) | Derivate und Analoge von Pyrimidon zur Behandlung von Asthma und bestimmte Hautkrankheiten. | |
| ATE160566T1 (de) | Amphotere tricyclische verbindungen als antihistaminische und antiallergische mittel | |
| TW275629B (pt) | ||
| ES2114477A1 (es) | Nuevas cafalosporinas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
| FF | Decision: intention to grant | ||
| HJEG | Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law | ||
| HIFF | Patent grant cancelled | ||
| FF | Decision: intention to grant | ||
| FG9A | Patent or certificate of addition granted | ||
| B24C | Patent annual fee: request for for restoration |
Free format text: REFERENTE A 14A, 15A E 16A ANUIDADE(S). |
|
| B24H | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi) | ||
| B24F | Patent annual fee: publication cancelled |
Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2257 DE 08/04/2014 POR TER SIDO INDEVIDA. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE AS 14A, 15A E 16A ANUIDADES. |
|
| B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |